The information contained on this web page is only a summary of information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement;
(II) Settlement Hearing; and (III) Motion for Attorneys’ Fees and Litigation Expenses (“Notice”), which you can access by clicking here.
Since this website is just a summary, you should review the Notice for additional details.
The Court-appointed Lead Plaintiff Arbejdsmarkedets Tillægspension (“Lead Plaintiff”), on behalf of itself and the Settlement Class, has settled the Action for $39,000,000 in cash (“Settlement”).
On November 8, 2023, the Court held a hearing to consider final approval of the Settlement and other matters. On November 14, 2023, the Court entered a final order approving the Settlement and Plan of Allocation and Lead Counsel’s motion for attorney's fees and litigation expenses, and a final Judgment.
If you are a member of the Settlement Class, your legal rights will be affected whether you act or do not act and you may be eligible for a payment from the Settlement. The Settlement Class consists of:
The Court-appointed Lead Plaintiff Arbejdsmarkedets Tillægspension (“Lead Plaintiff”), on behalf of itself and the Settlement Class, has settled the Action for $39,000,000 in cash (“Settlement”).
On November 8, 2023, the Court held a hearing to consider final approval of the Settlement and other matters. On November 14, 2023, the Court entered a final order approving the Settlement and Plan of Allocation and Lead Counsel’s motion for attorney's fees and litigation expenses, and a final Judgment.
If you are a member of the Settlement Class, your legal rights will be affected whether you act or do not act and you may be eligible for a payment from the Settlement. The Settlement Class consists of:
all persons and entities who purchased or otherwise acquired BioMarin common stock during the period from March 3, 2020 through August 18, 2020, inclusive, and were damaged thereby.
Certain persons and entities are excluded from the Settlement Class by definition (see paragraph 32 of the Notice) or if they requested exclusion pursuant to the instructions
set forth in the Notice.
Please read the Notice carefully to fully understand your rights.
The deadline for submission of a Claim Form to be potentially eligible to receive a payment from the Settlement was October 30, 2023.
Payments to eligible claimants will be made only if the Court approves the Settlement and a plan of allocation, and only after any appeals are resolved and the processing of all claims is complete. Please be patient, as this process will take some time to complete.
If you have questions, you may call the BioMarin Pharmaceutical Securities Settlement Helpline at (877) 390-3369 or email info@BioMarinSecuritiesLitigation.com.
Please read the Notice carefully to fully understand your rights.
The deadline for submission of a Claim Form to be potentially eligible to receive a payment from the Settlement was October 30, 2023.
Payments to eligible claimants will be made only if the Court approves the Settlement and a plan of allocation, and only after any appeals are resolved and the processing of all claims is complete. Please be patient, as this process will take some time to complete.
If you have questions, you may call the BioMarin Pharmaceutical Securities Settlement Helpline at (877) 390-3369 or email info@BioMarinSecuritiesLitigation.com.
PLEASE READ THE NOTICE CAREFULLY.